Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities

[In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine]

Natural killer-dendritic cell cross-talk in cancer immunotherapy

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia

Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

Natural-killer cells and dendritic cells: „l’union fait la force“